Medical Cannabis for the Treatment of Fibromyalgia
Medical Cannabis for the Treatment of Fibromyalgia
复制标题
DOI：
10.1097/rhu.0000000000000702
复制
发表时间：
2018-08-01
影响因子：
3.4
通讯作者：
Artul, Suheil
中科院分区：
文献类型：
--
作者：
Habib, George;Artul, Suheil
背景：纤维肌痛是一种慢性疼痛综合征，以慢性肌肉骨骼疼痛、疲劳和情绪障碍为特征。几乎没有医用大麻(MC)治疗纤维肌痛患者的数据。方法：数据来自以色列2家医院(拉尼亚多医院和拿撒勒医院)的登记资料，这些患者被诊断为纤维肌痛患者接受了MC治疗。征得患者同意后，记录人口统计学、临床和实验室参数。所有患者还完成了MC治疗前后修订的纤维肌痛影响问卷。结果：确定了30名患者，26名患者纳入研究。女性19例(73%)，研究组平均年龄37.8~7.6岁。MC的平均用量为26+/-8.3 g/月，平均使用时间为10.4+/-11.3个月。开始MC治疗后，所有患者在问卷上的各项参数都有显著改善，13名患者(50%)停止服用任何其他治疗纤维肌痛的药物。8例(30%)出现非常轻微的不良反应。结论：医用大麻治疗纤维肌痛疗效显著，不良反应少。
Background: Fibromyalgia is a chronic pain syndrome, characterized by chronic musculoskeletal pain, fatigue, and mood disturbances. There are nearly no data on the effect of medical cannabis (MC) treatment on patients with fibromyalgia.Methods: Data were obtained from the registries of 2 hospitals in Israel (Laniado Hospital and Nazareth Hospital) on patients with a diagnosis of fibromyalgia who were treated with MC. After obtaining patient consent, demographic, clinical, and laboratory parameters were documented. All the patients also completed the Revised Fibromyalgia Impact Questionnaire regarding the period before and after MC treatment.Results: Thirty patients were identified, and 26 patients were included in the study. There were 19 female patients (73%), and the mean age of the study group was 37.8 7.6 years. The mean dosage of MC was 26 +/- 8.3 g per month, and the mean duration of MC use was 10.4 +/- 11.3 months. After commencing MC treatment, all the patients reported a significant improvement in every parameter on the questionnaire, and 13 patients (50%) stopped taking any other medications for fibromyalgia. Eight patients (30%) experienced very mild adverse effects.Conclusions: Medical cannabis treatment had a significant favorable effect on patients with fibromyalgia, with few adverse effects.